Navigation Links
Global study reveals differences in standard of care for osteoporosis across the world
Date:5/27/2008

Barcelona, Spain, May 25 2008 In a first-of-its-kind study in osteoporosis, one in four women surveyed from Europe, North America, and Australia reported having one or more bone fractures since the age of 45 years. Among women considered to be at high risk for a fracture, only 26% reported use of bone-saving drugs, with use reported significantly less frequently in Europe than in North America and Australia. Identifying important regional differences is just one aim of a landmark observational study, the Global Longitudinal Registry of Osteoporosis in Women (GLOW), which will monitor the health of over 60,000 older women (≥55 yrs) worldwide for 5 years. Baseline results were presented today at the 35th European Symposium on Calcified Tissues.

For women enrolled in GLOW, fractures after the age of 45 were more prevalent in Europe than in the United States, Canada and Australia. For hip fracture specifically, a prior hip fracture was reported more frequently by women in Europe (2.1%) than by women in the United States (1.7%) or in Canada/Australia (1.4%). These potential differences will be further explored in follow-up years of the study.

We need to understand the cause for the regional differences we observe in fracture prevalence, said Dr Robert Lindsay, Professor of Clinical Medicine at Columbia University and GLOW executive committee co-chair. One aim of GLOW is to learn from those countries that are having the greatest success at preventing fractures and to recommend best practices that will improve the bone health and lives of millions of patients around the world.

To be eligible for this multi-national study, a woman had to be aged 55 years or older and had to have visited a primary care physician for any health reason in the two years prior to the study. Since patient recruitment for GLOW was not linked to osteoporosis, the study is meant to provide a view to the bone health and quality of care of typical community-dwelling women in multiple geographies.

In Europe, 51% of GLOW participants reported having a bone density test, a valuable tool for diagnosing osteoporosis. This contrasts to other geographies where testing frequency was reported at 79%. Among women considered to be at high risk of fracture, only 20% of European women were taking a bone medication versus 30% of North American/Australian women.

Despite reliable screening methods and multiple therapeutic options being available, osteoporosis remains largely under-diagnosed and under-treated, said Professor Pierre Delmas, Professor of medicine and rheumatology at University of Lyon, France, and GLOW executive committee co-chair. Without some improvements, the burden of fractures on our families and on our healthcare systems will only grow with the aging population.

Osteoporosis-related fractures are an international public health problem responsible for increased mortality, functional impairment and additional health care costs. , Direct costs of osteoporotic fractures in Europe alone are expected to rise from 31.7 billion in 2000 to 76.7 billion by 2050. In women over 45 years of age, osteoporosis accounts for more days spent in a hospital than diabetes, heart attack or breast cancer.

Hip fractures are the most serious of osteoporosis-related fractures, causing chronic pain, reduced mobility, disability, loss of independence and an increased risk of death.i,ii An estimated 179,000 men and 711,000 women in Europe suffer a hip fracture each year.iii


'/>"/>

Contact: Nicki Barwise
Nicola.Barwise@ketchum.com
44-776-682-8849
Ketchum
Source:Eurekalert

Related medicine news :

1. Corbett Selected to Host the Only Midwest Global Awards Judging Competition
2. Tata Consultancy Services to Support Roches Global Capacity Building Initiative
3. Creative Technology Services Enhances its Global Competitiveness with Additional Regulatory Certifications
4. Briefing on a new Web resource to address global drinking water crisis
5. MDS Pharma Services Wins Award for Management of Global Malaria Trial
6. Neusoft Becomes First Global Growth Company Partner of World Economic Forum
7. Resonant Medical Appoints New Vice President of Global Sales
8. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
9. The era of global aging: GSAs annual meeting to present new research on hot topics in aging
10. MEDEX Global Group & Harvard Medical International Join Forces to Create the Most Comprehensive Health Information Resource for International Travelers
11. Ultrasonix Adds Global Medical Imaging Into Its North American Sales Force
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... Los Angeles, CA (PRWEB) , ... August 17, 2017 , ... ... Hardiman partners Mark Hardiman, John Mills and Harry Nelson. This is the third consecutive ... row for Nelson. Hardiman and Nelson were both recognized for expertise in Health Care ...
(Date:8/17/2017)... California (PRWEB) , ... August 17, 2017 , ... An ... number of South Korean men obtaining plastic surgery, largely influenced by the growing popularity ... beauty clinic Beverly Hills Physicians notes that standards of male appearance are changing not ...
(Date:8/17/2017)... (PRWEB) , ... August 17, 2017 , ... Inc. Magazine ... Ranking at No. 132 with Three-Year Sales Growth of 3,004.8% , NEW YORK, August ... annual Inc. 5000, the most prestigious ranking of the nation's fastest-growing private companies. The ...
(Date:8/17/2017)... ... August 17, 2017 , ... Centrifugation is more than just spinning. Like ... we can no longer do without. And just like a car, there are a ... In this webinar, attendees will learn about the most important safety aspects while using ...
(Date:8/16/2017)... ... 2017 , ... Summer days spent with family are priceless. Since August is ... for enjoying the season of sunshine. Add trying something new to this summer’s bucket ... in on the fun. , Try Something New , Choose an ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)...  Axium Pharmaceuticals Inc., the creator of the drug Truveta ... stages of an IPO. The United States ... cost of a prescription epilepsy drug being $450.00-$1200.00 for a one month ... AXIUM PHARMACEUTICALS, INC ... Another staggering figure is the fact that Americans spent $42 billion on ...
(Date:8/14/2017)... and PETACH TIKVAH, Israel ... (NASDAQ: BCLI), a leading developer of adult stem cell ... second quarter ending June 30, 2017. ... of preparing for our pivotal Phase 3 trial to ... Lebovits , President and Chief Executive Officer of BrainStorm. ...
(Date:8/8/2017)...  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company ... results for the second quarter ended June 30, 2017. ... 2017 and to date: ... the Company,s lead project, BL-8040: Announced ... as novel stem cell mobilization treatment for autologous bone-marrow ...
Breaking Medicine Technology: